模块2:痉挛的非手术治疗

R. Reebye, A. Balbert, D. Bensmail, H. Walker, J. Wissel, T. Deltombe, G. Francisco
{"title":"模块2:痉挛的非手术治疗","authors":"R. Reebye, A. Balbert, D. Bensmail, H. Walker, J. Wissel, T. Deltombe, G. Francisco","doi":"10.4103/2349-7904.347808","DOIUrl":null,"url":null,"abstract":"Spasticity management should be part of a well-coordinated and comprehensive rehabilitation program that is patient-centric and goal-specific. There are a variety of options available for the treatment of spasticity. A usual approach is starting with the least invasive treatment modalities initially and gradually increasing to more complex interventions as this is required. This curriculum considers oral antispasticity drugs in terms of mechanism of action, clinical use, efficacy, and adverse events. It also presents other treatment options, such as chemical neurolysis using phenol and alcohol and chemodenervation using botulinum toxin A (BoNT-A). Therapeutic intramuscular injections of BoNT-A require sound patient selection, accurate muscle selection, and precise localization. The common methods for achieving these are described. The importance of physiotherapy is explained, along with the necessity to combine treatment modalities to address spasticity and the various components of the upper motor neuron syndrome. Recognizing differences in various health-care systems across countries and regions, the authors aim to present various treatment options. While this section of the curriculum highlights the importance of an interdisciplinary effort in managing spasticity, it is understandable that not all treatment options are available uniformly. The challenge to clinicians is to make the most of the management options on hand to optimize outcomes.","PeriodicalId":75125,"journal":{"name":"The journal of the International Society of Physical and Rehabilitation Medicine","volume":"5 1","pages":"23 - 37"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Module 2: Nonsurgical management of Spasticity\",\"authors\":\"R. Reebye, A. Balbert, D. Bensmail, H. Walker, J. Wissel, T. Deltombe, G. Francisco\",\"doi\":\"10.4103/2349-7904.347808\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Spasticity management should be part of a well-coordinated and comprehensive rehabilitation program that is patient-centric and goal-specific. There are a variety of options available for the treatment of spasticity. A usual approach is starting with the least invasive treatment modalities initially and gradually increasing to more complex interventions as this is required. This curriculum considers oral antispasticity drugs in terms of mechanism of action, clinical use, efficacy, and adverse events. It also presents other treatment options, such as chemical neurolysis using phenol and alcohol and chemodenervation using botulinum toxin A (BoNT-A). Therapeutic intramuscular injections of BoNT-A require sound patient selection, accurate muscle selection, and precise localization. The common methods for achieving these are described. The importance of physiotherapy is explained, along with the necessity to combine treatment modalities to address spasticity and the various components of the upper motor neuron syndrome. Recognizing differences in various health-care systems across countries and regions, the authors aim to present various treatment options. While this section of the curriculum highlights the importance of an interdisciplinary effort in managing spasticity, it is understandable that not all treatment options are available uniformly. The challenge to clinicians is to make the most of the management options on hand to optimize outcomes.\",\"PeriodicalId\":75125,\"journal\":{\"name\":\"The journal of the International Society of Physical and Rehabilitation Medicine\",\"volume\":\"5 1\",\"pages\":\"23 - 37\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The journal of the International Society of Physical and Rehabilitation Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/2349-7904.347808\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The journal of the International Society of Physical and Rehabilitation Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/2349-7904.347808","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

痉挛管理应该是一个协调良好、全面的康复计划的一部分,该计划以患者为中心,并针对特定目标。痉挛的治疗有多种选择。通常的方法是从最初的微创治疗模式开始,并根据需要逐渐增加到更复杂的干预措施。本课程从作用机制、临床应用、疗效和不良事件等方面考虑口服抗痉挛药物。它还提供了其他治疗选择,如使用苯酚和酒精的化学神经松解术和使用肉毒杆菌毒素A(BoNT-A)的化学去神经支配术。BoNT-A的治疗性肌内注射需要合理的患者选择、准确的肌肉选择和精确的定位。描述了实现这些功能的常用方法。解释了物理疗法的重要性,以及结合治疗方式来解决痉挛和上运动神经元综合征的各种组成部分的必要性。认识到各国和各地区不同医疗保健系统的差异,作者旨在提出各种治疗方案。虽然课程的这一部分强调了跨学科努力在管理痉挛方面的重要性,但可以理解的是,并非所有的治疗方案都是统一的。临床医生面临的挑战是充分利用现有的管理选择来优化结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Module 2: Nonsurgical management of Spasticity
Spasticity management should be part of a well-coordinated and comprehensive rehabilitation program that is patient-centric and goal-specific. There are a variety of options available for the treatment of spasticity. A usual approach is starting with the least invasive treatment modalities initially and gradually increasing to more complex interventions as this is required. This curriculum considers oral antispasticity drugs in terms of mechanism of action, clinical use, efficacy, and adverse events. It also presents other treatment options, such as chemical neurolysis using phenol and alcohol and chemodenervation using botulinum toxin A (BoNT-A). Therapeutic intramuscular injections of BoNT-A require sound patient selection, accurate muscle selection, and precise localization. The common methods for achieving these are described. The importance of physiotherapy is explained, along with the necessity to combine treatment modalities to address spasticity and the various components of the upper motor neuron syndrome. Recognizing differences in various health-care systems across countries and regions, the authors aim to present various treatment options. While this section of the curriculum highlights the importance of an interdisciplinary effort in managing spasticity, it is understandable that not all treatment options are available uniformly. The challenge to clinicians is to make the most of the management options on hand to optimize outcomes.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信